Hints and tips:
...value for Vectura shareholders in cash today,” said Bruno Angelici, Vectura’s chair....
...The tonic water maker said to expect only limited improvement next year as logistics problems combine with higher product and raw materials costs....
...Private equity takes the moral high ground We told you yesterday about private equity’s tussle with Big Tobacco for control of Vectura, a FTSE 250-listed company that sells inhalers....
...And they will continue to know that this preparation provides only limited protection,” said Josh Hardie, CBI deputy director-general. “For others, everything has changed....
...It also announced an expanded partnership with inhaler developer Vectura to clone GlaxoSmithKline’s Ellipta respiratory drug franchise....
...Balance sheets remain in very good shape and there is limited pressure on costs (especially land)....
...The rebound also follows Bruno Angelici, Vectura’s chairman, on Wednesday buying 75,000 shares. Peel Hunt repeated “hold” advice on Vectura....
...Vectura’s first-quarter update might still disappoint but, providing drug sales do not deteriorate, further downside looks limited as investors may now have written off generic Advair altogether, RBC said...
...Inhaler developer Vectura dropped 5.4 per cent to 106p, having been squeezed higher on Thursday by takeover speculation....
...“We are not convinced there is much equity value in Afren at $60 oil and still see it as limited at $80,” the broker said....
...Last week, Vectura received a €2.5m (£2.2m) milestone payment from Sandoz. Vectura is not yet profit-able due to its heavy research and development spending....
...And Vectura, the UK biotechnology company, is buying Innovata, the drug developer, for £130m in an all-share deal that will beef up its portfolio of treatments and increase sales....
...Vectura Group, which is developing a range of inhaler drugs, rose 9.8 per cent to 61.5p following a series of successful investor meetings....
International Edition